L. Mary Smith PH.D.
Net Worth

Last updated:

What is L. Mary Smith PH.D. net worth?

The estimated net worth of Dr. L. Mary Smith PH.D. is at least $11,860,167 as of 13 Oct 2021. He owns shares worth $7,869,667 as insider, has earned $1,369,700 from insider trading and has received compensation worth at least $2,620,800 in SpringWorks Therapeutics, Inc..

What is the salary of L. Mary Smith PH.D.?

Dr. L. Mary Smith PH.D. salary is $655,200 per year as Chief Devel. Officer in SpringWorks Therapeutics, Inc..

How old is L. Mary Smith PH.D.?

Dr. L. Mary Smith PH.D. is 58 years old, born in 1967.

What stocks does L. Mary Smith PH.D. currently own?

As insider, Dr. L. Mary Smith PH.D. owns shares in one company:

Company Title Shares Price per share Total value
SpringWorks Therapeutics, Inc. (SWTX) Chief Devel. Officer 167,511 $46.98 $7,869,667

What does SpringWorks Therapeutics, Inc. do?

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

SWTX logo
SWTX
SpringWorks Therapeutics, Inc.
$46.98

L. Mary Smith PH.D. insider trading

SpringWorks Therapeutics, Inc.

Dr. L. Mary Smith PH.D. has made 4 insider trades in 2021, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 10,000 units of SWTX stock on 20 Jan 2021. As of 13 Oct 2021 he still owns at least 167,511 units of SWTX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 10,000 $2.3 $23,000
Option
Stock Option (Right to Buy) 10,000 $2.3 $23,000
Sale
Common Stock 10,000 $55.97 $559,680
Option
Common Stock 10,000 N/A N/A
Option
Stock Option (Right to Buy) 10,000 N/A N/A
Sale
Common Stock 10,000 N/A N/A
Option
Common Stock 10,000 $2.3 $23,000
Option
Stock Option (Right to Buy) 10,000 $2.3 $23,000
Sale
Common Stock 10,000 $2.3 $23,000
Option
Common Stock 10,000 $1.98 $19,750
Sale
Common Stock 10,000 $78.7 $787,020
Option
Stock Option (Right to Buy) 10,000 $1.98 $19,750
Option
Common Stock 10,000 $1.98 $19,750
Option
Stock Option (Right to Buy) 10,000 $1.98 $19,750

SpringWorks Therapeutics key executives

SpringWorks Therapeutics, Inc. executives and other stock owners filed with the SEC: